Moderna
MRNA
$55.40
+6.27%
Moderna, Inc. is a commercial-stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, operating within the dynamic and high-risk biotech industry. The company established itself as a dominant platform player and market leader through the rapid validation and global deployment of its COVID-19 vaccine. The current investor narrative is intensely focused on the company's transition from a pandemic-driven entity to a sustainable, diversified biotech, with debates centering on the heavy strategic investments in its expansive pipeline of 35 clinical candidates—spanning oncology, infectious diseases, and rare diseases—against a backdrop of significant near-term losses and the lengthy path to commercializing its next major products.…
MRNA
Moderna
$55.40
Related headlines
Investment Opinion: Should I buy MRNA Today?
Rating: Hold. The core thesis is that Moderna is a high-risk, high-potential platform story in transition, currently priced for significant uncertainty, making it suitable only for speculative capital awaiting pipeline catalysts.
Supporting evidence includes a de-risked valuation at a PS of 5.90x, down sharply from its pandemic highs, and a fortress balance sheet (Debt/Equity: 0.22) that funds the $2.054 billion annual cash burn. Analysts project a return to profitability with an average EPS of $2.66, and the underlying gross margin of 55.35% is healthy. However, these positives are counterbalanced by a 29% YoY revenue decline and deeply negative cash flow, indicating the commercial payoff is distant.
The two biggest risks are the failure of a key pipeline candidate to reach the market, which would invalidate the platform narrative, and an acceleration of cash burn forcing dilutive financing. This Hold would upgrade to a Buy on positive Phase 3 data for a major pipeline asset (e.g., cancer or RSV vaccine) combined with a stabilization of quarterly revenue. It would downgrade to a Sell if quarterly revenue falls below $500 million or if the cash balance declines by more than $1 billion in a single year without a corresponding pipeline milestone. Relative to its own history, the stock is fairly valued for the current transitional phase, but it carries a significant premium to profitable biotechs, implying the market is still paying for future platform optionality.
Sign up to view all
MRNA 12-Month Price Forecast
Moderna is a binary, long-duration biotech bet currently in a holding pattern. The bullish platform potential is real, supported by 35 clinical candidates and a strong balance sheet, but it is squarely offset by severe near-term financial deterioration and a lack of revenue visibility. The neutral stance reflects the high probability (60%) of a base case where the stock churns within a range as the story slowly unfolds. Confidence is medium due to the wide dispersion in analyst estimates and the stock's sensitivity to single pipeline data points. The stance would upgrade to bullish on a clear pipeline win with commercial visibility, or downgrade to bearish on a clinical failure or a quarterly cash burn exceeding $700 million.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Moderna's 12-month outlook, with a consensus price target around $72.02 and implied upside of +30.0% versus the current price.
Average Target
$72.02
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$44 - $72
Analyst target range
Analyst coverage appears limited with only 9 analysts providing estimates, and explicit consensus price targets are not provided in the data set. The available data shows estimated revenue for the next period has a wide range from $5.76 billion to $10.14 billion, with an average of $6.82 billion, indicating high uncertainty about the near-term commercial trajectory. The estimated EPS average is $2.66, with a range from $2.12 to $4.34, pointing toward an expected return to profitability. Institutional ratings from the provided data show a mixed but leaning neutral sentiment, with recent actions including reiterations of 'Overweight', 'In Line', 'Sector Perform', 'Neutral', 'Equal Weight', and 'Underperform'. The absence of a clear consensus price target and the wide range in revenue estimates signal high uncertainty among analysts. This limited and mixed coverage is typical for a company in a major transitional phase, where outcomes are binary and long-dated, leading to higher stock volatility and less efficient price discovery as investors weigh the pipeline's potential against the substantial cash burn.
Bulls vs Bears: MRNA Investment Factors
The investment debate for Moderna centers on the tension between its validated platform with a deep pipeline and its severe near-term financial deterioration as COVID sales vanish. The bull case, supported by a strong balance sheet and de-risked valuation, currently holds stronger evidence for long-term, risk-tolerant investors. However, the bear case presents immediate and severe risks through massive cash burn and a lack of revenue diversification. The single most important factor that will resolve the thesis is the timeline and commercial success of its next major pipeline product; positive Phase 3 data for a key candidate would validate the strategy, while further delays would exacerbate cash burn concerns and likely lead to further multiple compression.
Bullish
- Strong Cash Runway & Low Debt: The company has a fortress balance sheet with a current ratio of 3.29 and a debt-to-equity ratio of 0.22, providing significant financial flexibility. This $2.6 billion cash position funds its aggressive R&D pipeline for years without leverage risk.
- Validated mRNA Platform with 35 Candidates: The core mRNA technology is validated by the COVID-19 vaccine, and the company now has 35 clinical candidates across oncology, infectious, and rare diseases. This expansive pipeline provides multiple shots on goal for the next blockbuster product.
- Attractive Valuation Relative to History: The stock trades at a Price-to-Sales (PS) ratio of 5.90x, near the low end of its recent historical range (Q4 2024: 16.75x, Q3 2025: 9.92x). This suggests the market has de-risked the transition from pandemic highs, offering a lower entry point for platform optionality.
- Analysts Expect Return to Profitability: Despite current losses, analysts project an average EPS of $2.66 for the next period, indicating a credible path to profitability. The wide range ($2.12 to $4.34) reflects uncertainty, but the consensus direction is positive.
Bearish
- Severe Revenue Decline & Lack of Diversification: Q4 2025 revenue of $678 million declined 29.08% YoY, and 100% of revenue comes from Product Sales (COVID vaccine). This highlights extreme volatility and a critical lack of commercial diversification as pandemic sales normalize.
- Massive Cash Burn & Deep Losses: The company is burning cash at a rate of -$2.054 billion (TTM FCF) with a net margin of -1.45% and ROE of -32.62%. These losses reflect heavy R&D investments with no near-term commercial returns, pressuring the valuation.
- High Uncertainty in Analyst Estimates: Analyst revenue estimates for the next period range widely from $5.76B to $10.14B, and institutional ratings are mixed ('Overweight' to 'Underperform'). This limited and conflicted coverage signals high uncertainty about the commercial timeline.
- Investor Impatience with Long Development Path: Recent news shows strong long-term cancer vaccine data was met with a stock drop, highlighting investor impatience. The path to commercializing the next major product is lengthy, creating a 'show me' story that may limit near-term upside.
MRNA Technical Analysis
The stock is in a powerful long-term uptrend but has recently entered a corrective phase. The 1-year price change of +82.49% and the 6-month gain of +69.42% underscore a sustained bullish trend from lower levels. Currently trading at $49.91, the price sits approximately 61% of the way up from its 52-week low of $22.28 towards its high of $59.55, indicating it has retreated meaningfully from recent peaks but remains in a higher intermediate range. Recent momentum has diverged sharply from the longer-term trend, signaling a potential consolidation or pullback. The 1-month price change is -1.01%, and the 3-month change is -5.04%, contrasting with the strong yearly performance and suggesting short-term profit-taking or waning momentum. This divergence is further evidenced by a 1-month relative strength of -0.93% versus the S&P 500. Key technical levels are clearly defined, with major support at the 52-week low of $22.28 and immediate resistance at the 52-week high of $59.55. A breakout above $59.55 would signal a resumption of the primary uptrend, while a breakdown below key support near $45 could indicate a deeper correction. With a beta of 1.03, the stock exhibits volatility roughly in line with the broader market, which is notable for a biotech name often prone to higher swings.
Beta
1.03
1.03x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$22-$60
Price range past year
Annual Return
+113.1%
Cumulative gain past year
| Period | MRNA Return | S&P 500 |
|---|---|---|
| 1m | +13.0% | +1.5% |
| 3m | +5.7% | +13.4% |
| 6m | +79.0% | +10.9% |
| 1y | +113.1% | +24.5% |
| ytd | +79.5% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MRNA Fundamental Analysis
Revenue is highly volatile and currently in a steep decline as COVID vaccine sales normalize, presenting a critical transition challenge. The most recent quarterly revenue (Q4 2025) was $678 million, representing a year-over-year decline of -29.08%. This follows a sequential pattern from Q3's $1.016 billion and Q2's $142 million, highlighting extreme quarterly volatility and an overall decelerating trend from pandemic peaks. The sole reported revenue segment is Product Sales at $1.052 billion, confirming the current lack of commercial diversification beyond its COVID vaccine. The company is deeply unprofitable as it invests heavily in its pipeline, with net income at -$826 million for Q4 2025 and a trailing net margin of -1.45%. However, the gross margin of 55.35% remains healthy, indicating the underlying profitability of its manufacturing platform when operational. The quarterly trend shows significant fluctuation, with Q3 2025 gross margin at a mere 0.79% due to high cost of revenue, rebounding to 33.33% in Q4, underscoring the lumpy nature of its current business. The balance sheet is a fortress of liquidity but cash burn is substantial. The company boasts a strong current ratio of 3.29 and a very low debt-to-equity ratio of 0.22, indicating minimal financial leverage risk. However, trailing twelve-month free cash flow is deeply negative at -$2.054 billion, and return on equity is -32.62%, reflecting the massive R&D investments that are not yet generating returns. The company's $2.6 billion in cash (from cash flow statements) provides a multi-year runway but underscores the urgency to advance its pipeline to commercialization.
Quarterly Revenue
$678000000.0B
2025-12
Revenue YoY Growth
-0.29%
YoY Comparison
Gross Margin
+0.33%
Latest Quarter
Free Cash Flow
$-2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MRNA Overvalued?
Given the negative net income, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is 5.90x, which prices the company at a significant sales multiple despite declining revenue. The forward-looking valuation is not directly comparable as a forward PS is unavailable, but the market is clearly valuing the platform and pipeline potential rather than current sales. Compared to industry averages, specific sector multiples are not provided in the data, making a direct peer comparison unavailable. The valuation must therefore be assessed on its own historical context and the narrative of pipeline optionality. Historically, the stock's own PS ratio has fluctuated wildly, from extremes above 200x during peak pandemic sales to a recent low of 9.92x in Q3 2025. The current 5.90x PS is near the lower end of its own recent historical range (Q4 2024: 16.75x, Q3 2025: 9.92x), suggesting the market has significantly de-risked the stock from its pandemic highs and is pricing in a challenging transition period with limited near-term sales growth.
PE
-4.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -13x~495x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-4.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are acute. Moderna's revenue is in steep decline (-29.08% YoY in Q4) and entirely concentrated in its COVID vaccine, creating a volatile, single-product business model. The company is burning cash at a rate of -$2.054 billion annually with a deeply negative ROE of -32.62%, reflecting massive R&D investments that may not yield commercial products for years. While the $2.6 billion cash balance provides a runway, the urgency to advance the pipeline is high, and any clinical setbacks would accelerate the cash burn timeline.
Market & Competitive Risks are significant. The stock's valuation, while lower historically, still carries a PS ratio of 5.90x for a company with declining sales and heavy losses, leaving it vulnerable to further multiple compression if growth fails to materialize. Competitive intensity in mRNA and adjacent vaccine/therapeutic spaces is high, with news highlighting rival Novavax's sales beats. Furthermore, with a beta of 1.03, the stock's volatility is in line with the market, but its narrative-driven price swings (evident in the 52-week range of $22.28 to $59.55) expose it to sector rotation away from high-risk, long-duration biotech assets.
The Worst-Case Scenario involves a combination of pipeline failures and accelerated cash burn. Key clinical candidates fail in late-stage trials, the COVID revenue base erodes faster than expected, and the company is forced to raise dilutive capital or cut R&D spending drastically to preserve cash. In this adverse scenario, the stock could realistically re-test its 52-week low of $22.28, representing a downside of approximately -55% from the current price of $49.91. The historical max drawdown of -35.51% provides a reference for the volatility already priced in, but a fundamental deterioration could lead to deeper losses.
FAQ
The key risks are, in order of severity: 1) Clinical & Pipeline Risk: Failure of a lead candidate would invalidate the platform narrative and crash the stock. 2) Financial Risk: The company is burning -$2.054 billion annually; accelerated burn could force dilutive financing within 2 years. 3) Commercialization Risk: Revenue is declining 29% YoY and is 100% dependent on the COVID vaccine, with no near-term diversified product. 4) Competitive & Regulatory Risk: Intense competition in mRNA and vaccine spaces, plus potential regulatory hurdles for new products.
The 12-month forecast is a range-bound outcome with high volatility around pipeline data. The base case (60% probability) sees the stock trading between $45 and $55 as the company continues its R&D investments with managed revenue decline. The bull case (25%) targets $59.55 to $70+ on positive pivotal trial data. The bear case (15%) warns of a drop to $22.28-$35 on a clinical failure or worsening finances. The most likely scenario is the base case, assuming the company hits its clinical milestones but the commercial payoff remains beyond the 12-month horizon.
MRNA is fairly valued relative to its current transitional phase but carries a premium based on future potential. The trailing PS ratio of 5.90x is near the low end of its own recent historical range (from 9.92x to 16.75x), suggesting the market has priced in the near-term revenue decline. However, this multiple is still applied to a company with negative earnings and cash flow, implying the market is paying for the optionality of its 35-candidate pipeline. Compared to profitable biotech peers, it is overvalued on earnings, but for a platform story, the current price reflects a balanced risk/reward.
MRNA is a speculative buy only for investors with a high-risk tolerance and a long-term horizon. The stock offers significant upside (analyst EPS estimates average $2.66) if its pipeline succeeds, but carries severe downside risk, with potential to fall 55% to its 52-week low of $22.28 if clinical trials fail or cash burn accelerates. Given the current Hold rating, it is not a good buy for conservative or income-seeking investors, but aggressive investors might find the de-risked 5.90x PS ratio an attractive entry point for the platform optionality.
MRNA is strictly a long-term investment for a speculative portion of a portfolio. The lengthy clinical development timeline (next major product likely 2+ years away) and high cash burn make it unsuitable for short-term trading, despite its beta of 1.03 and recent volatility. The stock's value will be determined by pipeline successes over the next 3-5 years, not quarterly fluctuations. Investors should be prepared to hold for a minimum of 3-5 years to see the platform story play out, and must tolerate significant price swings along the way.